Allogene Therapeutics, Inc.
ALLO
$1.45
$0.053.57%
NASDAQ
| 12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | 12/31/2023 | |
|---|---|---|---|---|---|
| Revenue | 22.00K | 43.00K | 65.00K | 87.00K | 95.00K |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | 22.00K | 43.00K | 65.00K | 87.00K | 95.00K |
| Cost of Revenue | 192.30M | 201.99M | 203.25M | 214.94M | 242.91M |
| Gross Profit | -192.28M | -201.95M | -203.19M | -214.85M | -242.82M |
| SG&A Expenses | 65.21M | 66.91M | 67.62M | 70.06M | 71.67M |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 257.50M | 268.90M | 270.87M | 284.99M | 314.59M |
| Operating Income | -257.48M | -268.86M | -270.81M | -284.90M | -314.49M |
| Income Before Tax | -257.15M | -283.43M | -279.42M | -292.30M | -327.27M |
| Income Tax Expenses | 443.00K | -- | -- | -- | -- |
| Earnings from Continuing Operations | -257.59 | -283.43 | -279.42 | -292.30 | -327.27 |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -257.59M | -283.43M | -279.42M | -292.30M | -327.27M |
| EBIT | -257.48M | -268.86M | -270.81M | -284.90M | -314.49M |
| EBITDA | -243.84M | -254.97M | -256.56M | -270.66M | -300.29M |
| EPS Basic | -1.34 | -1.56 | -1.61 | -1.81 | -2.11 |
| Normalized Basic EPS | -0.78 | -0.86 | -0.92 | -1.05 | -1.25 |
| EPS Diluted | -1.34 | -1.56 | -1.61 | -1.81 | -2.11 |
| Normalized Diluted EPS | -0.78 | -0.86 | -0.92 | -1.05 | -1.25 |
| Average Basic Shares Outstanding | 778.92M | 736.68M | 695.14M | 651.91M | 627.34M |
| Average Diluted Shares Outstanding | 778.92M | 736.68M | 695.14M | 651.91M | 627.34M |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |